Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


At EuroPCR: Drug-Eluting Stents From Asia, But At What Cost?

Executive Summary

No one would place drug-eluting stents among the hot technologies showcased at this year’s EuroPCR, not with all the buzz around renal denervation, percutaneous valves, and bioabsorbable stents and scaffolds. But an early morning session on DES from India and China underscored how the technology debate is changing in a world of cost constraints and emerging markets, particularly for mature categories.

You may also be interested in...

EuroPCR 2013: The Calm After The Technology Storm

For the past several years, TAVI and renal denervation have dominated EuroPCR, the largest interventional cardiology conference in Europe. This year’s conference in Paris in May was a bit more balanced, leaving room for interest in bioresorbable stents and mitral valves.

Reinvigorating The Coronary Stent Market: Can Bioresorbable Scaffolds Do The Job?

Bioresorbable coronary scaffolds could transform the coronary stenting market once they become widely available. But although there are more than a dozen companies developing these promising devices, there are still a number of unanswered questions – chief among them, how effectively they will compete against existing and upcoming next-generation durable stents, and how much of a price premium bioresorbable devices will be able to command.

Amunix Raises $117m To Take Novel T-Cell Engager Into The Clinic

Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts